Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.42 |
| ▸ | POLR1A | O95602 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13575604 | 0.92 | USP30 (0.58) | USP30PDE4BHDAC4HDAC6PDE4A | |
| SCHEMBL10143889 | 0.92 | USP30 (0.58) | USP30PDE4BHDAC4HDAC6PDE4A | |
| SCHEMBL3546076 | 0.89 | HDAC4 (0.52) | USP30PDE4BHDAC4HDAC6PDE4A | |
| SCHEMBL12426663 | 0.84 | HTR4 (0.56) | PDE4BHTR4HDAC1HDAC2PDE4A | |
| SCHEMBL15706793 | 0.82 | USP30 (0.54) | USP30HDAC4HDAC6GABRA5POLR1A | |
| SCHEMBL13175766 | 0.82 | HTR4 (0.50) | USP30HTR4 | |
| SCHEMBL12426326 | 0.82 | USP30 (0.46) | USP30PDE4BHTR4PDE4APDE4C | |
| SCHEMBL4542499 | 0.82 | ALDH1A1 (0.52) | PDE4BHDAC1HDAC2EHMT2 | |
| SCHEMBL12426368 | 0.82 | HPGDS (0.47) | HTR4 | |
| SCHEMBL14215967 | 0.82 | PDE4B (0.46) | USP30PDE4BHTR4HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003785-B2 | Halo-substituted pyrimidodiazepines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| WO-2009153197-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | USP30 3379/4885PDE4B 3392/4885HDAC4 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.